Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
1. Merck announced Phase 3 data on doravirine/islatravir for HIV-1 treatment. 2. DOR/ISL showed non-inferiority to Biktarvy in maintaining viral suppression. 3. Weight changes were minimal between DOR/ISL and Biktarvy treatment groups. 4. FDA accepted the New Drug Application for DOR/ISL, action date April 2026. 5. MRK shares fell by 0.96% to $83.89 at publication.